Catalyst Brief

← Calendar

ReadoutIn window

Hoffmann-La Roche — Atezolizumab

Phase 3 primary completion: A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A).

Date
Nov 2026
Type
Readout
Indication
Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Hoffmann-La Roche

  1. Mar2027
    Readoutin 104d
    Hoffmann-La Roche — Atezolizumab
    Phase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy.
  2. Feb2027
    Readoutin 76d
    Hoffmann-La Roche — Ranibizumab
    Phase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome).
  3. Jan2027
    Readoutin 45d
    Hoffmann-La Roche — Afimkibart
    Phase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis.